Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?

Area of Science:

• Oncology
• Pharmacology
• Cancer Metastasis Research

Background:

• Cancer cell motility is a key driver of metastasis.
• Current treatments often focus on cytotoxicity or antiproliferative effects.
• There is a need for novel therapeutic strategies targeting cancer cell migration.

Purpose of the Study:

• To introduce the concept of migrastatics as a new drug class.
• To highlight the potential of targeting cancer cell motility for antimetastatic therapy.
• To advocate for the development of migrastatic drugs.

Main Methods:

• Conceptual framework development.
• Review of existing migrastatic candidates.
• Analysis of potential regulatory pathways.

Main Results:

• Migrastatics represent a distinct class of drugs.
• These drugs inhibit cancer cell motility without being cytotoxic or antiproliferative.
• Migrastatic candidates have been identified.

Conclusions:

• Migrastatics offer a promising new avenue for cancer treatment.
• The development of migrastatic drugs is timely and feasible.
• This approach could lead to a new era in antimetastatic therapy.